Uğur Akar

Uğur Akar

Authors' Affiliations: Departments Of Breast Medical Oncology, Experimental Therapeutics, Cancer Biology, And Stem Cell Transplantation And Cellular Therapy, The University Of ...

Direct Impact

Concepts for which Uğur Akar has direct influence:

breast cancer
gingival hyperplasia
translation initiation
tissue transglutaminase
alopecia areata
therapeutic silencing
retinoic acid

External impact

Concepts related to the work of other authors for which Uğur Akar has influence:

pulmonary metastasis
mammalian target
increased angiogenesis
acute promyelocytic leukemia
basal epithelial phenotype
breast cancer
melanoma cells

Prominent publications by Uğur Akar

KOL-Index: 33 Translation initiation and activity of eukaryotic initiation factor-alpha (eIF2α), the rate-limiting step of translation initiation, is often overactivated in malignant cells. Here, we investigated the regulation and role of eIF2α in acute promyelocytic (APL) and acute myeloid leukemia (AML) cells in response to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), the front-line ...
Known for
P-Eif2α Protein Expression | Eukaryotic Initiation Factor-Alpha | Perk | U937
KOL-Index: 27 More than 75% of breast cancers that develop in BRCA1 mutation carriers are triple-negative breast cancers (TNBC). The aim of this study was to compare the recurrence-free survival (RFS) and overall survival (OS) in high-risk patients with TNBC with and without deleterious BRCA1/2 mutations. A total of 227 women with TNBC who were referred for genetic counseling and underwent BRCA genetic ...
KOL-Index: 23 Overexpression of p70S6K in breast cancer patients is associated with aggressive disease and poor prognosis. Recent studies showed that patients with breast cancer with increased p70S6K phosphorylation had poor survival and increased metastasis. The purpose of our study was to determine whether knockdown of p70S6K would inhibit cell growth, invasion, and metastasis in breast cancer. We ...
Known for
Lentiviral Short Hairpin | Mda-231 Shrna Cells | Key Proteins | P70s6k Expression
KOL-Index: 22 The selective estrogen receptor modulators (SERM), Tamoxifen and raloxifen reduce risk breast cancer. Patient acceptance of SERMs for breast cancer prevention is low due to toxicities. New agents with a better toxicity profile are needed. Aromatase inhibitors (AI) reduce the risk of contralateral breast cancer and risk of new breast cancer in high risk women. However, the mechanism by which ...
Known for
Reduce Breast | Toxicity Profile | Modulation Serum | Prospective Short-Term Prevention
KOL-Index: 20 The epidermal growth factor receptor (EGFR) signaling pathway has emerged as a promising target for cancer therapy. EGFR tyrosine kinase inhibitors (TKI) such as erlotinib have been approved for cancer treatment but have shown very limited activity in breast cancer patients. Clarifying the molecular mechanism underlying resistance to EGFR TKIs could lead to more effective treatment against ...
Known for
Vivo Kis Gene | Enhanced Erlotinib-Mediated Cytotoxicity | Nuclear Protein | Orthotopic Breast Cancer Xenograft
KOL-Index: 16 Bcl-2 is overexpressed in about a half of human cancers and 50-70% of breast cancer patients, thereby conferring resistance to conventional therapies and making it an excellent therapeutic target. Small interfering RNA (siRNA) offers novel and powerful tools for specific gene silencing and molecularly targeted therapy. Here, we show that therapeutic silencing of Bcl-2 by systemically ...
Known for
Bcl-2 Systemically | Robust Persistent Silencing | 50-70 | Molecular Therapy-Nucleic Acids
KOL-Index: 15 Melanoma is the most aggressive form of skin cancer. The rising incidence of melanoma and its poor prognosis in advanced stages are compelling reasons to identify novel therapeutic agents. Though isolated dietary components such as lycopene, resveratrol, and isothiocyanate compounds have been shown to provide limited protection against cancer development, the use of whole herbs and herbal ...
Known for
Inflammatory Pathway Products | Unique Multiherbal Extract Preparation | Proliferation Zyflamend | Autophagy-Apoptosis Switch
KOL-Index: 14 PARP inhibitors are considered promising anticancer agents and currently being tested in clinical trials in hereditary breast cancer patients harboring mutations in BRCA1 and BRCA2 genes. In this study, we investigated the antiproliferative effects and mechanism of PARP inhibitors ABT-888 (Veliparib), BSI-201 (Iniparib) and AZD228 (Olaparib) in breast cancer cell lines with BRCA1 or BRCA2 ...
Known for
Brca1 Mutant | Breast Cancer Lines | Brca Allelic | Loss Azd2281
KOL-Index: 14 Programmed cell death-4 (PDCD4) is a recently discovered tumor suppressor protein that inhibits protein synthesis by suppression of translation initiation. We investigated the role and the regulation of PDCD4 in the terminal differentiation of acute myeloid leukemia (AML) cells. Expression of PDCD4 was markedly up-regulated during all-trans retinoic acid (ATRA)-induced granulocytic ...
Known for
Cells Atra | Pdcd4 Protein | Tissue Transglutaminase | Differentiation Nb4
KOL-Index: 13
Known for
Antigen Alleles

Authors' Affiliations: Departments of Breast Medical Oncology, Experimental Therapeutics, Cancer Biology, and Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172